Literature DB >> 2545782

Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.

S Lederman1, R Gulick, L Chess.   

Abstract

Dextran sulfate, heparin, and certain other sulfated polysaccharides potently inhibit the adsorption of HIV to CD4+ cells. The mechanism of this inhibition is unclear and, specifically, it is unknown if these agents act at the level of CD4-gp120 binding. For example, previous reports have demonstrated that dextran sulfate does not inhibit the cell surface binding of anti-CD4 mAb known to be directed at the gp120 binding site. In order to confirm and extend these observations, in the present study, it was shown that dextran sulfate does not inhibit the binding of OKT4A, OKT4C, Leu3a, or B66.6 to CD4+ cells as measured by cytofluorography. Next, recombinant forms of CD4 (rT4) and gp120 (rgp120) were utilized to directly study their molecular interaction in the absence of other viral or cellular structures. Reciprocal solid phase ELISA assays were developed to study directly the effects of sulfated polysaccharides on the binding of rT4 to immobilized rgp120 and vice versa. Dextran sulfate, heparin, and fucoidan, but not chondroitin sulfate, inhibited the binding of rgp120 to rT4. Importantly, dextran sulfate and heparin pre-treatment of immobilized rT4, but not immobilized rgp120, inhibited rT4-rgp120 binding. Taken together, these data suggest that while both sulfated polysaccharides and anti-CD4 mAb inhibit gp120 binding, the sulfated polysaccharides interact with sites on CD4 that are distinct from those with which the antibodies bind.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545782

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Authors:  Cagan Gurer; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Sulfated polyanions do not inhibit duck hepatitis B virus infection.

Authors:  W B Offensperger; S Offensperger; E Walter; H E Blum; W Gerok
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 4.  Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development.

Authors:  Colleen R Eade; Matthew P Wood; Alexander M Cole
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

Review 5.  The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection.

Authors:  C C Rider
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

6.  Quantitation of a lentivirus in its natural host: simian immunodeficiency virus in African green monkeys.

Authors:  S Hartung; K Boller; K Cichutek; S G Norley; R Kurth
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay.

Authors:  B L Lohman; J Higgins; M L Marthas; P A Marx; N C Pedersen
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.

Authors:  A L Stone; D J Melton; M S Lewis
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

10.  Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds.

Authors:  P R Meylan; R S Kornbluth; I Zbinden; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.